T7717

Sodium 2-oxopropanoate (Sodium pyruvate) is a antioxidant potentially used to treatment of chronic obstructive pulmonary disease.

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.

Efineptakin alfa (NT-17), a long-acting recombinant human interleukin-7 (IL-7), promotes the proliferation and survival of CD4+ and CD8+ cells in both humans and mice. It has applications in glioblastoma research [1].

Eflapegrastim, a humanized IgG4 monoclonal antibody and granulocyte colony-stimulating factor (G-CSF), targets the G-CSF receptor (c-Fms). It promotes the proliferation and differentiation of neutrophil progenitor cells, ensuring a stable count of mature and functional neutrophils, and effectively shortens the duration of neutropenia [1].

Eflepedocokin alfa is a recombinant fusion protein comprising human IL-22 fused with the human IgG2-Fc domain, exhibiting cell protective activity. It activates the IL-22/IL-22R-mediated signal transduction pathways, including STAT3, playing a critical role in immune response to bacterial infections. It enhances intestinal barrier function, boosts intestinal immunity, and facilitates tissue repair [1].

Efmarodocokin alfa, a fusion protein combining human IL-22 with the IgG4 crystallizable fragment, activates IL-22 signaling. This compound has potential applications in the study of severe COVID-19 pneumonia [1].

Efruxifermin, an Fc-FGF21 fusion protein consisting of a human IgG1 Fc domain linked to modified human FGF21, exhibits a prolonged half-life and enhanced receptor affinity compared to its native counterpart. It is utilized in researching non-alcoholic steatohepatitis [1].

Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation and exhibiting antitumour activity.

Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.

Pucotenlimab (HX008) is a humanized IgG4 monoclonal antibody that specifically targets the programmed cell death protein 1 (PD-1) immune checkpoint. it potently blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby restoring the ability of immune cells to target and eliminate cancer cells, Pucotenlimab can be used in studies about a wide range of solid tumours.

Remtolumab (ABT-122), a dual-variable domain immunoglobulin, neutralizes tumor necrosis factor α (TNFα) and IL-17A, demonstrating dual inhibition of both. This compound is utilized in rheumatoid arthritis (RA) research [1] [2].